{"name":"Chengdu Zenitar Biomedical Technology Co., Ltd","slug":"chengdu-zenitar-biomedical-technology-co-ltd","ticker":"","exchange":"","domain":"chengduzenitarbiomedicaltechnology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Flonoltinib Maleate","genericName":"Flonoltinib Maleate","slug":"flonoltinib-maleate","indication":"Chronic myeloid leukemia (CML)","status":"phase_2"},{"name":"Purinostat Mesylate for Injection","genericName":"Purinostat Mesylate for Injection","slug":"purinostat-mesylate-for-injection","indication":"Relapsed or refractory peripheral T-cell lymphoma","status":"phase_3"},{"name":"Selinexor Tablets","genericName":"Selinexor Tablets","slug":"selinexor-tablets","indication":"Multiple myeloma (in combination with dexamethasone)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Extended Phase Dose Group","genericName":"Extended Phase Dose Group","slug":"extended-phase-dose-group","indication":"Other","status":"phase_2"},{"name":"flunotinib","genericName":"flunotinib","slug":"flunotinib","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Extended Phase Dose Group","genericName":"Extended Phase Dose Group","slug":"extended-phase-dose-group","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Flonoltinib Maleate","genericName":"Flonoltinib Maleate","slug":"flonoltinib-maleate","phase":"phase_2","mechanism":"Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein.","indications":["Chronic myeloid leukemia (CML)","Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)"],"catalyst":""},{"name":"Purinostat Mesylate for Injection","genericName":"Purinostat Mesylate for Injection","slug":"purinostat-mesylate-for-injection","phase":"phase_3","mechanism":"Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression.","indications":["Relapsed or refractory peripheral T-cell lymphoma"],"catalyst":""},{"name":"Selinexor Tablets","genericName":"Selinexor Tablets","slug":"selinexor-tablets","phase":"phase_3","mechanism":"Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation.","indications":["Multiple myeloma (in combination with dexamethasone)","Diffuse large B-cell lymphoma (DLBCL)","Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"flunotinib","genericName":"flunotinib","slug":"flunotinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9GZ2d1aHBXN0dGUXZ2THRGSlBnbElKRTZKczZWR0MzelBmWVZOY3FKd1FjcndVVUNHUjc4N3FGR1JGOG5QeFgteG1MNmdPZlZRMFZzazZkVXlBWmRGVE5j?oc=5","date":"2025-03-12","type":"pipeline","source":"Nature","summary":"A structure-based framework for selective inhibitor design and optimization - Nature","headline":"A structure-based framework for selective inhibitor design and optimization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5rVDFkU3FZajYtakRzVXFLeTBDNTlUWFhSejJhWWhHZ3dWR0p2TjlkeG9qb25CQVJTQ2tOT0NkNnRfLWJiMmhOdHZWT0p0dkVoYXJmLWJ2Unl5a2xTUFRv?oc=5","date":"2022-03-07","type":"pipeline","source":"Nature","summary":"Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2 - Nature","headline":"Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":2,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}